SCYNEXIS, Inc. (SCYX)
Oxford Ledge is still expanding full research coverage of SCYX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
SCYNEXIS develops novel antifungal drugs targeting drug-resistant fungal infections, with one FDA-approved product and another in clinical trials.
SEC filings
- 8-K Amendments to articles or bylaws; Shareholder vote results; Other material event; Financial statements and exhibits 2026-06-26
- 8-K Amendments to articles or bylaws; Financial statements and exhibits 2026-05-29
- 8-K Shareholder vote results; Other material event 2026-05-22
- 10-Q Quarterly financial report (unaudited) 2026-05-11
- DEF 14A Proxy statement for shareholder vote 2026-04-30
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for SCYX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open SCYX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.